The Proof-of-Concept of MBA121, a Tacrine–Ferulic Acid Hybrid, for Alzheimer’s Disease Therapy

The Proof-of-Concept of MBA121, a Tacrine–Ferulic Acid Hybrid, for Alzheimer’s Disease Therapy

Great effort has been devoted to the synthesis of novel multi-target directed tacrine derivatives in the search of new treatments for Alzheimer’s disease (AD). Herein we describe the proof of concept of MBA121, a compound designed as a tacrine–ferulic acid hybrid, and its potential use in the therap...

Full description

Bibliographic Details
Main Authors: Emelina R. Rodríguez-Ruiz, Raquel Herrero-Labrador, Ana P. Fernández-Fernández, Julia Serrano-Masa, José A. Martínez-Montero, Daniel González-Nieto, Mayuri Hana-Vaish, Mohamed Benchekroun, Lhassane Ismaili, José Marco-Contelles, Ricardo Martínez-Murillo
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:International Journal of Molecular Sciences
Subjects:
Alzheimer’s disease
beta amyloid
APP<sub>swe</sub>/PS1<sub>ΔE9</sub>
cerebral cortex
ferulic acid
hippocampus
Online Access:https://www.mdpi.com/1422-0067/24/15/12254

Internet

https://www.mdpi.com/1422-0067/24/15/12254

Similar Items